Viking Therapeutics VKTX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's total liabilities & equity?
- Viking Therapeutics (VKTX) reported total liabilities & equity of $608.24M in Q1 2026.
- How has Viking Therapeutics's total liabilities & equity changed year-over-year?
- Viking Therapeutics's total liabilities & equity decreased by 29.8% year-over-year, from $866.99M to $608.24M.
- What is the long-term trend for Viking Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Viking Therapeutics's total liabilities & equity has grown at a 22.8% compound annual growth rate (CAGR), from $256.5M to $715.73M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.